Recent preclinical and clinical studies have highlighted that targeting the GDF15‐GFRAL signalling pathway is a promising approach for treating obesity, particularly because it has minimal impact on skeletal muscle mass, which is essential to preserve during weight loss. This evidence concerns the gene GFRAL and obesity disorder.